Advanced search×

Breast cancer risk in relation to the interval between menopause and starting hormone therapy.

V Beral, G Reeves, D Bull, and J Green

J Natl Cancer Inst 103(4):296-305 (2011) PMID 21278356

Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only formulations of menopausal hormonal therapy, reports on their effects have been somewhat inconsistent. We investigated whether the timing of these therapies affected breast cancer incidence.

DOI: 10.1093/jnci/djq527
Version: za2963e q8za1 q8zb5 q8zc4 q8zdc q8ze7 q8zfb q8zg0

Similar articles you may find interesting…

  1. Measurement issues related to lipoprotein heterogeneity.
    James D JD Otvos, Elias J EJ Jeyarajah, and William C WC Cromwell

    Am J Cardiol 90(8A):22i-29i (2002) PMID 12419478

    In clinical practice, the coronary artery disease (CAD) risk associated with high levels of low-density lipoprotein (LDL) or low levels of high-density lipoprotein (HDL) is assessed not by measuring LDL and HDL particles directly, but by measuring the amount of cholesterol carried by these lipoprote...